Neurotoxicity of Drugs of Abuse

Neurotoxicity of Drugs of Abuse

1st Edition - September 1, 2022

Write a review

  • Editors: Lucio Costa, Michael Aschner, William Slikker, Jr.
  • Hardcover ISBN: 9780323915854

Purchase options

Purchase options
Available for Pre-Order
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order


Neurotoxicity of Drugs of Abuse, Volume Eight provides carefully crafted reviews on the disruptive impact of drugs of abuse on the central nervous system. The neurotoxicity potential of several agents including amphetamines, fentanyl and ketamine are carefully reviewed, and their short-term and chronic effects are categorized. Pharmacokinetic profiles as well as mechanisms of action for these and other drugs of abuse such as alcohol, nicotine and marijuana are also evaluated. The implications of long-term abuse for agents such as PCP, cocaine and MDMA are also characterized. Drugs covered in this release include Amphetamine/Cocaine, Opioids, Nicotine, Marijuana, Alcohol, Fentanyl, MDMA and Ketamine. Readers will come away with a full understanding of the adverse effects of drugs of abuse on the nervous system.

Key Features

  • Summarizes both the short and long-term adverse effects of drugs of abuse on the nervous system
  • Describes potential mechanisms of action of centrally acting drugs of abuse
  • Covers Amphetamine/Cocaine, Opioids, Nicotine, Marijuana, Alcohol, Fentanyl, MDMA and Ketamine


Basic researchers, clinicians, epidemiologists, regulators, drug developers, chemists

Table of Contents

  • 1. Amphetamine/Cocaine
    Syed Z. Imam
    2. Opioids
    David Thorn
    3. Nicotine
    Edward D. Levin
    4. Marijuana
    Gaylia Jean Harry
    5. Alcohol
    Miriam Beatríz Virgolini
    6. Fentanyl
    R. Dan Mellon
    7. MDMA
    Syed F. Ali
    8. PCP
    Cheng Wang
    9. Ketamine
    Donald Mattison

Product details

  • No. of pages: 300
  • Language: English
  • Copyright: © Academic Press 2022
  • Published: September 1, 2022
  • Imprint: Academic Press
  • Hardcover ISBN: 9780323915854

About the Serial Volume Editors

Lucio Costa

Lucio Costa
Dr. Lucio G. Costa is Professor of Toxicology at the University of Washington in Seattle, and of Pharmacology/Toxicology at the University of Parma Medical School. He received a doctorate in Pharmacology from the University of Milano in 1977, and was a postdoctoral fellow at the University of Texas at Houston. He is a member of several national and international professional organizations, a Fellow of the Academy of Toxicological Sciences, and a European Certified Toxicologist. He received various award for his scientific accomplishments, including the Achievement Award from the Society of Toxicology. He serves in various editorial capacities for several toxicology journals, and is an active manuscript and grant reviewer. Dr. Costa has been the member of dozens of panels and committees at the national and international level dealing with toxicology and risk assessment issues. He has chaired and/or organized symposia at scientific meetings in the United States and internationally. He has been teaching classes in the area of toxicology, neurotoxicology and pharmacology to graduate and medical students for 30 years. He keeps an active research program in the area of neurotoxicology.

Affiliations and Expertise

Professor of Toxicology, University of Washington, Seattle, WA, USA

Michael Aschner

Michael Aschner
Dr. Aschner serves as the Harold and Muriel Block Chair in Molecular Pharmacology at Albert Einstein College of Medicine. He served on numerous toxicology panels (Institute of Medicine, US Environmental Protection Agency, Center for Disease Control), and is a member of the Neurotoxicology and Alcohol study section (NIH). Research in our lab focuses on the following topics: (1) Modulation of C. elegans genes (aat, skn-1, daf-16) that are homologous to mammalian regulators of MeHg uptake and cellular resistance will modify dopaminergic neurodegeneration in response to MeHg exposure. (2) Under conditions of MeHg-induced oxidative stress, Nrf2 (a master regulator of antioxidant responses) coordinates the upregulation of cytoprotective genes that combat MeHg-induced oxidative injury, and that genetic and biochemical changes that negatively impact upon Nrf2 function increase MeHg’s neurotoxicity. (3) PARK2, a strong PD genetic risk factor, alters neuronal vulnerability to modifiers of cellular Mn status, particularly at the level of mitochondrial dysfunction and oxidative stress. Our studies are designed to (1) shed novel mechanistic insight into metal-induced neurodegeneration; (2) identify targets for genetic or pharmacologic modulation of neurodegenerative disorders; (3) increase knowledge of the pathway involved in oxidative stress; (4) develop improved research models for human disease using knowledge of environmental sciences.

Affiliations and Expertise

Professor, Department of Molecular Pharmacology, Albert Einstein College of Medicine, NY, USA

William Slikker, Jr.

William Slikker, Jr.
Dr. William Slikker, Jr. is the director of FDA’s National Center for Toxicological Research (NCTR). He received his Ph.D. in pharmacology and toxicology from the University of California at Davis. Dr. Slikker holds adjunct professorships in the Department of Pediatrics, as well as the Department of Pharmacology and Toxicology at the University of Arkansas for Medical Sciences. He has held committee chairmanships or elected offices in several scientific societies including the Teratology Society (serving as president) and the American Society for Pharmacology and Experimental Therapeutics (chair, Developmental Pharmacology Section and member, Program Committee). Dr. Slikker is also the co-founder and past president of the MidSouth Computational Biology and Bioinformatics Society. He is currently associate editor for NeuroToxicology and associate editor for the “Environmental Health” section of Experimental Biology and Medicine. He is the past president of The Academy of Toxicological Sciences and the Society of Toxicology. He is a recipient of the 2014 George H. Scott Memorial Award from The Toxicology Forum and was invited to present the Warkany Lecture at the 2015 annual meeting of the Teratology Society. In early 2019, the Academy of Toxicological Sciences selected Dr. Slikker to receive the prestigious Mildred S. Christian Career Achievement Award. The Society for Birth Defects Research and Prevention selected Dr. Slikker to be the recipient of the 2022 Edward W. Carney Distinguished Service Award. Dr. Slikker has authored or co-authored over 380 publications in the areas of transplancental pharmacokinetics, developmental neurotoxicology, neuroprotection, systems biology, and risk assessment. Dr. Slikker’s recent research has highlighted the concern for thousands of infants and toddlers who undergo longer-duration general anesthesia. He has performed research with his team and published over 25 peer-reviewed papers outlining the issue of brain-cell death and cognitive-function deficits in animal models that may result from several hours of anesthesia at a critical time of development. He has also, with the use of in vitro and in vivo techniques in rodents and nonhuman primates, defined possible mechanisms of toxicity and protective pathways to prevent the detrimental effects of general anesthesia. Through these and related scientific contributions, he has identified and characterized a host of minimally invasive biomarkers of neurotoxicity including the use of preclinical imaging (MRI, MicroPET/CT), genomic and lipidomic analysis, and modeling approaches to characterize and quantify adult and developmental neurotoxicity. He has also served on several national/international advisory panels for ILSI, HESI, CIIT, EPA, NIEHS, NAS, NIH and WHO.

Affiliations and Expertise

National Center for Toxicological Research, Jefferson, US FDA, AR, USA

Ratings and Reviews

Write a review

There are currently no reviews for "Neurotoxicity of Drugs of Abuse"